-
Diagnostics World News | Point-of-care testing devices are getting smarter, but better planning on the front end can mean fewer disappointments for technology developers trying to win market acceptance of their products and care providers hoping to use them in real-world practice settings.
Nov 13, 2019
-
Diagnostics World News | Advances in microfluidic cell sorting techniques at the University of Washington is allowing for highly precise isolation and analysis of tumor-derived rare cells and extracellular vesicles at high- throughput speed.
Nov 12, 2019
-
Diagnostics World News | Massachusetts General Hospital has developed liquid biopsy technologies to do high-throughput exosome protein profiling and point-of-care exosome analysis.
Nov 8, 2019
-
Diagnostics World News | Exosomes are promising targets for liquid biopsy diagnostics, but they’ve proven difficult to quickly capture and analyze. Oregon Health & Science University scientists are helping to overcome this hurdle with an alternating current electrokinetic microarray chip that integrates the isolation and analysis of exosomes and cell-free DNA biomarkers from a drop of blood.
Nov 6, 2019
-
Diagnostics World News | Companies looking to commercialize rapid diagnostics technologies might want to borrow from the playbook of those who successfully brought their point-of-care (POC) products to market.
Nov 5, 2019
-
Diagnostics World News | Precision medicine promises treatment strategies tailored to individual patient characteristics and tumor biology. But improved health outcomes won’t happen without access to healthcare and molecular testing, which can differ substantially by geography and even within individual countries.
Nov 1, 2019
-
Diagnostics World News | October featured news, products, and partnerships from around the diagnostics community from numerous companies, universities, and organizations, including Illumina, QIAGEN, Optibrium, and more.
Oct 31, 2019
-
Diagnostics World News | The value of liquid biopsies in precision medicine, particularly for managing cancers where tissue samples from tumors and metastatic sites are hard if not impossible to obtain, is a major topic of conversation, as tests that look for circulating tumor cells and circulating tumor DNA are enjoying a "resurgence" in clinical trials.
Oct 29, 2019